Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: A study in Nagasaki Prefecture, Japan

International Journal of Hematology

Volumn 85, Issue 2, 2007, Pages 132-139

  Matsuo, Emi ^a   Miyazaki, Yasushi ^a,c   Tsutsumi, Chizuko ^a   Inoue, Yoriko ^a   Yamasaki, Reishi ^a   Hata, Tomoko ^a   Fukushima, Takuya ^a   Tsushima, Hideki ^a   Imanishi, Daisuke ^a   Imaizumi, Yoshitaka ^a   Iwanaga, Masako ^a   Sakai, Mari ^a   Ando, Koji ^a   Sawayama, Yasushi ^a   Ogawa, Daisuke ^a   Kawaguchi, Yasuhisa ^a   Nagai, Kazuhiro ^a   Tsukasaki, Kunihiro ^a   Ikeda, Shuichi ^b   Moriuchi, Yukiyoshi ^b   Yoshida, Shinichiro ^b   Honda, Miyuki ^b   Taguchi, Jun ^b   Onimaru, Yasuyuki ^b   Tsuchiya, Takeshi ^b   Tawara, Masayuki ^b   Atogami, Sunao ^b   Yamamura, Masaomi ^b   Soda, Hisashi ^b   Yoshida, Yoshiharu ^b   Matsuo, Yuji ^b   Nonaka, Hiroaki ^b   Joh, Tatsuro ^b   Takasaki, Yumi ^b   Kawasaki, Chiyuki ^b   Momita, Saburo ^b   Jinnai, Itsuro ^b   Kuriyama, Kazutaka ^b   Tomonaga, Masao ^a   more..

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Nagasaki CML Study Group   (Japan)

^c NONE   (Japan)

Author keywords

Chronic myelogenous leukemia; Cytogenetic response; Imatinib; Molecular response; New diagnosis; Previous diagnosis

Indexed keywords

CREATINE KINASE; IMATINIB;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; CYTOPENIA; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME BLOOD LEVEL; EVALUATION; FEMALE; FEVER; FLUID RETENTION; FOLLOW UP; HUMAN; INFECTION; JAPAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHLEGMON; RASH; SIDE EFFECT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CREATINE KINASE; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION;

EID: 33847678637     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06157     Document Type: Article

References (22)

1. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
2. Borthakur G, Cortes JE. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol. 2004;79:411-419.
3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653.
4. O'Brien SG, Guilhot F, Larson RA, et al, for the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
5. Hughes TM, Kaeda J, Branford S, et al, for the International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
6. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460-466.
7. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-4407.
8. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004;104:2655-2660.
9. Bonifazi F, de Vivo A, Rosti G, et al, for the European Study Group on Interferon in Chronic Myeloid Leukemia. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood. 2001;98:3074-3081.
10. Kim YJ, Kim DW, Lee S, et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol. 2002;68:272-280.
11. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2001;97:1560-1565.
12. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17:2401-2409.
13. Wright JR, Bouma S, Dayes I, et al. The importance of reporting patient recruitment details in phase III trials. J Clin Oncol. 2006;24:843-845.
14. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283.
15. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can preexist to the onset of treatment. Blood. 2002;100:1014-1018.
16. Soda M, Ikeda T, Matsuo T, Suyama A. Cancer incidence in Nagasaki prefecture 1993-1997. In: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, eds. Cancer Incidence in Five Continents Vol. VIII. Lyon, France: International Agency for Research on Cancer/International Association of Cancer Registry; 2003:390-393.
17. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425-3432.
18. Morishima Y, Ogura M, Nishimura M, et al. Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int J Hematol. 2004;80:261-266.
19. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
20. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
21. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475.
22. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878.